key: cord-0997007-fhsz55qv authors: Pistone, Aureliano; Tant, Laure; Soyfoo, Muhammad S title: Clinical course of COVID-19 infection in inflammatory rheumatologic patients: a monocentric Belgian experience date: 2020-11-05 journal: Rheumatol Adv Pract DOI: 10.1093/rap/rkaa055 sha: 9874136c3f1932c54dda8088a4fcedb79830fb5e doc_id: 997007 cord_uid: fhsz55qv OBJECTIVES: Little is known about the incidence and consequences of COVID-19 infection in patients with rheumatic diseases. To improve our knowledge in this field, we collected data from patients with inflammatory rheumatic diseases, who developed COVID-19 infection. PATIENTS AND METHODS: We performed a monocentric observational longitudinal study and collected retrospectively data from patients with inflammatory rheumatic diseases who developed a confirmed or suspected COVID-19 infection between 3rd March and 10th June 2020. RESULTS: A total of 23 patients developed COVID-19 infection. Seven patients needed hospitalization (female 57%, mean age 59 ± 9 years) and sixteen patients were followed as outpatients (female 80%, mean age 50 ± 14 years). All hospitalized patients had more than one comorbidity. At the time of infection, all patients were on immunosuppressive therapy consisting of either csDMARDs and/or biotherapy with and without corticosteroids. A minority received corticosteroids only. The most common symptoms of COVID-19 infected patients were fever, dyspnoea, cough, and fatigue. Polymerase Chain Reaction (PCR) and chest computed tomography (CT) were performed in all hospitalized patients to confirm the diagnosis (100% positive PCR, 71% positive CT). All outclinic patients were clinically diagnosed (confirmed by PCR in only one). The mean length of hospital stay was 21 ± 19 days. Three patients developed an Acute Respiratory Distress Syndrome including one who died. CONCLUSIONS: A limited number of patients with inflammatory rheumatic diseases suffered from COVID-19 infection. Two patients needed mechanical ventilation and survived, while one patient died. All patients with severe form of infection had at least one comorbidity. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) emerged in China at the end of December 2019. In February, coronavirus disease 2019 was officially related to the virus. This infection is mainly characterized by pulmonary involvement. Within a few weeks, COVID-19 infection spread very rapidly throughout the world to such an extent that the World Health Organization (WHO) declared the pandemic state on March 11, 2020 (1). To date, COVID-19 pandemic has wreaked havoc causing the death of more than a 850.000 people worldwide. Belgium as well as several European countries has confined its population from March 17 to May 11, 2020 in order to prevent the overburdening of medical departments. The peak rate of new confirmed cases was reached on the 9 th April 2020. In the last epidemiological report (August 31, 2020), the Belgian health institute Sciensano estimated that 85,042 people were infected and 9,894 people died from COVID-19 in Belgium (2). As such, COVID-19 infection is typically complicated by hypoxemic interstitial pneumonia that can progress to a severe acute respiratory distress syndrome (ARDS) requiring intensive care. Several converging lines of evidence suggest that clinical deterioration towards multiple organ failure is related to a cytokine storm (3) . Indeed, following viral infection an inadequate immune response triggers unabated production of pro-inflammatory cytokines leading to a systemic and fulminant hyper-inflammatory syndrome. Therefore, several immunosuppressive molecules have been proposed in clinical studies for the treatment of life-threatening cases, such as Tocilizumab, Sarilumab, corticosteroids, Anakinra or Baricitinib (4). These drugs are well known and largely prescribed by rheumatologists for the treatment of rheumatic inflammatory diseases such as rheumatoid arthritis (RA). Several concerns cropped up when first cases series were published concerning the potential risk of COVID-19 linked to https://mc.manuscriptcentral.com/rheumap immunosuppression in patients with chronic inflammatory diseases (5) (6) (7) . Immunosuppressive therapy as such and disease-induced immunosuppression carry the risk of infection in general (8) . On the other hand, the anti-inflammatory and anti-cytokinic action of the immunosuppressive therapies could have curbed the excessive immune response induced by the virus (9) . Actually, few cases of severe COVID-19 infection have been reported in patients with inflammatory diseases treated with immunosuppressant drugs, specially in China (10) but in Italy (11) and in Spain as well (12, 13) . In each country, the incidence of COVID-19 confirmed patients with immune-mediated disease was consistent with the general population. The low incidence of severe cases reported among patients with inflammatory diseases receiving immunosuppressive therapy, particularly in areas with a high rate of contamination, suggests that these patients are not at risk of developing SARS-CoV2 infection (6, 12, 14, 15) . In patients with inflammatory rheumatic diseases who developed the virus, the unfavourable development towards ARDS was associated with the presence of the same comorbidities as those described in the Chinese and Italian population (9) . An in depth analysis of cases that developed in China enabled to delineate several risk factors for disease severity and prognosis such as male sex, obesity, the presence of underlying diabetes, arterial hypertension, cardiovascular diseases or cancer (16) . Conversely, the potential efficacy of these immunosuppressive drugs to treat patients with worsened prognosis prompted the rheumatologic scholar societies to recommend maintaining immunosuppressive treatments during the pandemic in chronically treated patients without obvious clinical suspicion of COVID-19 infection (17) (18) (19) . Currently, there is scant data about the exact prevalence and the specific evolution of COVID-19 infection in patients with immune-mediated inflammatory diseases. The risk of poor disease outcome in this population is unclear, as well as their susceptibility related to the underlying disease or the presence of associated diseases and the administration of specific medications. To improve our knowledge in this new field of clinical disease, we conducted a single-center observational study to clinically characterize patients with chronic inflammatory rheumatic diseases who developed symptoms compatible with COVID-19. This monocentric observational longitudinal study was performed at the Erasme Hospital in Brussels (Belgium), and was approved by the local Ethics Committee. This study complies with the Declaration of Helsinki and informed consent has been obtained from the subjects (or their legally authorized representative). We collected retrospectively data from patients with inflammatory rheumatic diseases who A total of 26 patients were selected. An alternative diagnosis was found in 3 patients: a pneumocystis jiroveci infection, an interstitial lung disease and a non covid-19 atypical pneumonia. They were therefore excluded from the analysis. Demographics and clinical characteristics of the 23 patients are described in table 1. Eight patients were diagnosed with RA, 3 with axial spondyloarthritis (SpA), 3 with peripheral SpA, 6 with psoriatic arthritis (PsA), 2 with primary Sjögren's syndrome (SS) and 1 systemic lupus erythematosus (SLE). Seven patients needed hospitalization (female 57%, mean age 59 ± 9 years) and sixteen patients were followed as outpatients (female 80%, mean age 50 ± 14 years). All hospitalized patients presented more than one comorbidity. At the time of infection, patients were on immunosuppressive therapy with corticosteroids (2 hospitalized patients vs 3 outpatients), conventional synthetic disease-modifying antirheumatic drug (csDMARDs) (4 hospitalized patients vs 11 outpatients) and/or biotherapy (5 hospitalized patients vs 12 outpatients). The most common symptoms of COVID-19 infected patients were in order of decreasing frequency fever, dyspnoea, cough and fatigue. Polymerase Chain Reaction (PCR) and chest computed tomography (CT) were performed in all hospitalized patients to confirm the diagnosis (100% positive PCR, 71% positive CT). All outclinic patients were clinically diagnosed (confirmed by PCR in only one). Hydroxychloroquine was administered to 86% of hospitalized patients. At the time of infection diagnosis, all hospitalized patients and 5 out of 12 outpatients discontinued biotherapy. The mean length of hospital stay was 21 ± 19 days. Three patients developed an ARDS and 2 patients needed invasive mechanical ventilation hence, admission to the intensive care unit (ICU). These two patients with endotracheal intubation were treated by csDMARDs with biological agents and had an underlying chronic pulmonary disease. The third patient with ARDS, also suffered from advanced blood cancer and chronic obstructive pulmonary disease (COPD). Because of his poor haematological prognosis, this patient was not transferred to the ICU. He received non-invasive ventilation but unfortunately died. All of these 3 patients had general and respiratory symptoms, had been diagnosed by PCR and chest CT, and received hydroxychloroquine. Only one patient in ICU received Lopinavir. The median hospitalization duration was 42 ± 10 days for patients with mechanical ventilation and 6 ± 2 days for those without ventilation. During hospitalization, biologic therapies (4 patients with bDMARDs and 1 with tsDMARDs) and csDMARDs (3 patients with methotrexate) were discontinued in all patients. Corticosteroids were continued, as well hydroxychloroquine. Azathioprine was also continued in a patient with sarcoidosis. During the follow-up, negative PCR tests for 4 previously hospitalized patients under bDMARDs allowed them to restart their treatment. The patient on tsDMARDs did not resume treatment because of stable remission. Indeed, at the beginning of the epidemic of COVID-19, there were several questions that still remained shrouded regarding the safety of biologic therapies in PCR positive patients; and more specially in inflammatory bowel disease patients. (20) In this context, we decided as a safety mesure to check PCR negativity before restarting biologic treatment. The median time between first symptom and PCR negativity was 43 ± 17 days (range 20 -64). To our knowledge, this series of cases is the first data collection in Belgium of patients suffering from inflammatory diseases presenting symptoms compatible with COVID-19 infection. We Outclinic patients reported less pyrexia but more myalgia and dyspnoea. In particular, the occurrence of anosmia and / or agueusia is reported in 30% of cases. This symptom seems specific for COVID-19 infection. It has been reported to be present in nearly 55% of cases and sometimes be the sole clinical feature related to COVID-19 (23, 24) . The difference between clinical symptoms in hospitalized and non-hospitalized patients can be explained by a subjective and retrospective collection of data, specially for outclinic patients. Objective data such as pyrexia may be unreliable. Furthermore, the anxiety-provoking context of the epidemic may have exacerbated the feeling of dyspnoea. All of hospitalized patients had at least one comorbidity. Considering all patients infected, 39% were obese, 30% had arterial hypertension and 17% had diabetes. This feature has been described soon after the beginning of the epidemic in China. The characteristics of patients who progressed to ARDS or died were published to highlight the risk factors for poor outcome. In a series of 191 patients, almost half had comorbidities, including in order of frequency, high blood pressure, diabetes and cardiovascular diseases (16) . The COVID-19 Global Rheumatology Alliance registry including patients with rheumatic diseases also reported a higher number of comorbidities in hospitalized patients: hypertension was the most represented, followed by chronic pulmonary diseases, diabetes, cardiovascular diseases and renal insufficiencies (25) . The data from our cohort therefore confirm the same results: most patients with one or more comorbidity have developed more severe damage. However, it is interesting to note that a third of the obese patients included in our cohort required hospitalization. Several studies have shown the susceptibility to SARS-CoV2 of obese individuals, particularly in Europe (Italy, Spain, France and UK) and in the US. Overweight is associated with an increased risk of admission to ICU (26) . Among the hospitalized patients, one patient died. This patient, aged 71 years, had primary Sjögren's syndrome complicated by a malignant hemopathy for which he was undergoing treatment with azacitidine. He developed rapid respiratory failure which did not respond favourably to non-invasive ventilation. His prognosis was limited and with the agreement of his family, he did not benefit from intensive care. In this cohort, the most frequent rheumatic diseases were RA, followed by PsA, axial and peripheral SpA. Five patients were on corticosteroid therapy, including 1 with a dosage above 10 mg per day of prednisone equivalent. Seventy percent of patients received biotherapy, mostly anti-TNF, and 22% were treated by targeted DMARD therapy. Among the most severe cases, we observed that the 2 intubated patients were treated with Infliximab and Baricitinib. The deceased patient was treated by corticosteroids alone because of the concomitant haematological complication. The influence of DMARDs and biotherapies on the severity of COVID-19 infection remains debated (27) . Recent data from the European register suggests that treatments with DMARDs do not increase the risk of hospitalization. The odds of hospitalization would be reduced by the use of anti-TNF treatments but increased by the administration of glucocorticoids with dosage of more than 10 mg per day of equivalent prednisone (16) . The mortality in patients with inflammatory diseases treated with biological-or targeted DMARD does not seem to differ from the general population (12) . Rheumatologists were therefore invited to continue rheumatological treatments in their patients as long as they showed no signs of COVID-19 infection and had not been exposed to SARS-CoV2 (16, 17, 19) . Inhibition of interleukin 6 (IL6) via the administration of Tocilizumab or Sarilumab, or Janus kinasesinhibitors, such as Baricitinib, has been proposed as forays in patients with severe disease. The unfavourable evolution towards an ARDS and / or a multi-organ failure has been attributed to a cytokine storm induced by an unbridled immune response of the host in response to the viral infection (28) . SARS-CoV2 induces rapid Th1-type lymphocyte activation entailing the production of pro-inflammatory cytokines (TNF, IL6, but also IL1, vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 (MCP-1), IL-8,…). The administration of IL6R-antagonists for the treatment of COVID is currently under study. In two small case series, IL-6 inhibition seems to have a positive effect on survival (29, 30) . The number of patients included being very limited; no conclusion can be raised today. Baricitinib (a janus kinase 1 and 2 inhibitor) has also been assessed as a potential candidate by its high ability to bind AAK1 (AP2-associated protein kinase 1), one of the regulatory proteins involved in endocytosis. Inactivation of this protein could prevent the virus from entering the lung epithelial cells. However, by its action on the JAK-STAT pathway, Baricitinib reduces the production of IFN alpha, which is cardinal for viral elimination. Its potential effect is still widely debated (31) (32) (33) . Our study has many limitations. First of all, the small number of patients included prevents any statistical analysis and does not allow for any conclusions to be drawn. The data were collected retrospectively, which may have led to an under-evaluation of clinical symptoms and chronological inaccuracies. We included patients who reported compatible symptoms during a telephone or physical consultation or following a spontaneous call from them. We therefore probably omitted pauci-symptomatic patients or patients who did not inform us about the occurrence of their symptoms. However, the data collection lasted more than 3 months after the first hospitalization. This time corresponds to the mean time between 2 successive consultations for the usual follow-up of patients. All patients with an appointment scheduled since the start of Belgian confinement were contacted by phone. In addition, patients with inflammatory rheumatic diseases followed in our department have been educated to reach our rheumatology nurse by phone if they have any complication. These measures do not allow us to certify having captured all moderate to severe cases but, it is highly unlikely that a patient with a severe form was missed. All patients who presented symptoms compatible with COVID-19 were included. The patients followed on an outclinic basis did not benefit from PCR screening. However, it was deemed necessary to maintain these patients in our analysis in order to avoid excluding patients with milder features and to have real life data patients. A limited number of patients with inflammatory rheumatic diseases developed COVID-19 infection. Two patients needed intubation and survived while one patient with advanced hemopathy died. All patients with a severe form of infection had comorbidities. We did not highlight a particular clinical pattern in hospitalized patients or outpatients. This observational study was limited to cases reported to us, probably underestimating the number of patients with SARS-CoV2 infection. COVID-19: consider cytokine storm syndromes and immunosuppression The cytokine storm and COVID-19 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet SARS-CoV-2 infection among patients with systemic autoimmune diseases What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic Clinical features of rheumatic patients infected with COVID-19 in Wuhan Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheumatol Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak. Dig Liver Dis Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China Clinical Characteristics of Coronavirus Disease 2019 in China Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (COVID-19) How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review On the Alert for Cytokine Storm: Immunopathology in COVID-19 Effective treatment of severe COVID-19 patients with tocilizumab Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration. medRxiv Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact We thank Céline La, Julie Sarrand, Sandra Kleimberg, Joelle Margaux, Farida Benhadou and FrédéricVandergheynst for their help in collecting patients. No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article. The authors have declared no conflicts of interest.https://mc.manuscriptcentral.com/rheumap Hospitalized patients Outpatients Number of patients 23 7 16 Age (years) (mean ± SD) 53 ± 13 59 ± 9 50 ± 14 Female, n (%) 12 c. PCR and Chest CT were performed on all hospitalized patients but only in a single outpatient. d. This value is calculated from four patients for who a PCR control was performed. Mean time until PCR negativity in the 4 patients for whom PCR monitoring was carried out. Abbreviations: BMI = Body Mass Index, COPD = Chronic Obstructive Pulmonary Disease, VICD = Variable Common Immune Deficiency, SpA= Spondyloarthritis; csDMARDs = conventional synthetic disease-modifying antirheumatic drug, bDMARDs = biological disease-modifying antirheumatic drug, tsDMARDs = targeted synthetic disease-modifying antirheumatic drug, PCR = Polymerase Chain Reaction, ICU = Intensive Care Unit, CT = Computed Tomography, ARDS =Acute Respiratory Distress Syndrome.